Gemcitabine plus carboplatin used as induction regimen for elderly patients with locally advanced unresectable non-small cell lung cancer

Objective:The purpose of this study was to evaluate the efficacy and safety of gemcitabine(GEM) and carboplatin(CBP) used as induction regimen in the treatment of elderly patients with locally advanced unresectable non-small cell lung cancer(NSCLC).Methods:Seventy-eight cases of elderly patients have been cytologically and pathologically confirmed with locally advanced unresectable NSCLC,the age of the patients ranged from 65 to 75 years.The patients were treated with the combined regimen of gemcitabine and cisplatin.GEM 1000 mg/m2 intravenously injected by drip on the 1st,8th day and the dosage of CBP was AUC 4 that was used on the 1st day,21 days apart to each cycle,most patients received 2 cycles.Treatment response was evaluated according to the criteria of RECIST(Response Evaluation Criteria in Solid Tumor),the side effect of the regimen was judged based on WHO criteria.Results:Seventy-eight patients were evaluated and received a total of 156 cycles chemotherapy.There were no complete regression that could be observed,but 32 cases had partial regression(PR),37 cases with no change(NC) and 9 cases with progression disease(PD).The overall response rate was 41.0%.The main side effects were hematological toxicity.Conclusion:The GC regimen could be used as induction treatment for elderly patients with locally advanced unresectable NSCLC,and the regimen could be well tolerated and is safe in terms of side effects.

Clinical observation of docetaxel in treating advanced non-small cell lung cancer in the elderly patients

Objective:The aim of our study was to evaluate the clinical efficacy and side effects of docetaxel as single chemotherapy for elderly patients with advanced non-small-cell lung cancer (NSCLC). Methods: Forty-two elderly patients with advanced NSCLC who were chemotherapy-naive were enrolled in this study. Docetaxel at the doses of 70 mg/m2 was administrated intravenously every 21 days as a cycle, each patient received 2-4 cycles. All patients were followed up until disease progressed or patients died. Results: Among 42 patients, 40 could be evaluated, 1 complete response (CR), 9 partial response (PR), 13 stable disease (SD), 17 progress disease (PD). The overall response rate (CR+PR) was 35% and disease control rate (CR+PR+SD) was 57.5%. The median time to progress (TTP) was 4.2 months, median survival time was 6.1 months and 1-year survival rate was 35.8%. The main toxicity was myelosuppression and decreasing platelet. Conclusion: Single agent docetaxel for elderly patients with advanced NSCLC is an efficient and well-tolerated chemotherapeutic approach with a low toxicity level.

吉非替尼治疗老年晚期非小细胞肺癌不良反应的护理

目的探讨吉非替尼单药治疗老年晚期非小细胞肺癌的疗效及护理方法。方法选择27例老年晚期非小细胞肺癌患者吉非替尼单药治疗90d后,评价其疗效及不良反应,并对用药期间的护理进行回顾性分析,总结护理经验。结果本组患者治疗有效率为29.63%(8/27),疾病控制率为74.07%(20/27);不良反应有皮疹13例(48.15%),恶心呕吐12例(44.44%),腹泻9例(33.33%),肝功能异常3例(11.11%),口腔溃疡2例(7.41%)。结论用药前进行宣教,用药期间加强观察,及时发现不良反应,并进行护理干预和对症处理,可保证用药安全,提高患者的舒适度和治疗依从性,改善生活质量。

112例老年晚期非小细胞肺癌病人一线应用EGFR-TKIs的疗效及安全性观察

目的观察在晚期老年非小细胞肺癌患者中一线应用EGFR-TKIs靶向治疗药物的疗效及安全性。方法选取70岁以上晚期非小细胞肺癌患者共112例,应用吉非替尼(250 mg 1次/d口服)68例,应用厄洛替尼(150 mg 1次/d口服)15例,应用埃可替尼(125 mg 3次/d口服)29例。观察患者接受EGFR-TKIs治疗的疗效、不良反应及无进展生存期(PFS)。结果 112例患者接受EGFR-TKIs治疗,共109例完成治疗,本组无CR病例,26例患者获得PR,42例患者疗效为SD,41例患者PD,有效率(ORR)23.8%,疾病控制率(DCR)62.4%。3例不能耐受而中止用药。全组患者中位无进展生存期(m PFS)为6.0个月。吉非替尼、厄洛替尼、埃可替尼各组间疗效无明显差异,P>0.05。结论晚期老年非小细胞肺癌患者应用EGFR-TKIs靶向治疗药物安全有效,不良反应轻微,可耐受。吉非替尼、厄洛替尼、埃可替尼疗效无明显差异。